Odyssey Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income $38.3 million.
“Net loss was $38.3 million for the quarter ended March 31, 2026, compared to a net loss of $38.4 million for the same period in 2025.”
Odyssey Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Odyssey Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Odyssey Therapeutics, Inc. entered into Share Purchase Agreement with TPG LSI Rise Orazio II, L.P. (effective 2026-05-07).
“On May 7, 2026, Odyssey Therapeutics, Inc. (the " Company ") entered into a Share Purchase Agreement (the " Purchase Agreement ") with TPG LSI Rise Orazio II, L.P. (" Purchaser "), an affiliate of an existing stockholder of the Company, for the purchase of an aggregate of 1,388,889 shares (the " Shares ") of the Company’s common stock, par value $0.001 (the " Common Stock "), at a per share price equal to the initial public offering price of $18.00 per share, through a private placement financing (the " Private Placement "), which closed concurrently with the initial public offering of shares of the Company’s Common Stock (the " IPO ").”
Odyssey Therapeutics, Inc.: Effective May 11, 2026, in connection with its IPO, the Company adopted amended and restated bylaws approved by the board and stockholders (effective 2026-05-11).
“Effective as of May 11, 2026, the Company adopted amended and restated bylaws (the “ Amended and Restated Bylaws ”) in connection with the closing of the IPO. The Board and stockholders previously approved the Amended and Restated Bylaws to be effective immediately prior to the closing of the IPO.”
Odyssey Therapeutics, Inc.: On May 11, 2026, in connection with its IPO, the Company filed an amended and restated certificate of incorporation approved by the board and stockholders (effective 2026-05-11).
“In connection with the closing of the IPO, on May 11, 2026, the Company filed an amended and restated certificate of incorporation (the “ Amended and Restated Certificate of Incorporation ”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “ Board ”) and stockholders previously approved the Amended and Restated Certificate of Incorporation to be effective as of immediately prior to the closing of the IPO.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.